As mentioned previously, it has been suggested that SGLT2 inhibitors (e.g., empagliflozin) may improve cardiovascular outcomes in people with T2D via increasing myocardial ketone body oxidation rates (Lopaschuk and Verma, 2016). The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.